Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Cancer Vaccines01:30

Cancer Vaccines

1.3K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

85.8K
Overview
85.8K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

17.0K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
17.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial Expression of Concern: Recognition of the nonclassical MHC class I molecule H2-M3 by the receptor Ly49A regulates the licensing and activation of NK cells.

Nature immunology·2026
Same author

Correction: Contribution of IL-17-producing γδ T cells to the efficacy of anticancer chemotherapy.

The Journal of experimental medicine·2026
Same author

Author Correction: IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting.

Nature communications·2024
Same author

TIGIT predominantly regulates the immune response via regulatory T cells.

The Journal of clinical investigation·2024
Same author

NK cell heparanase controls tumor invasion and immune surveillance.

The Journal of clinical investigation·2024
Same author

Correction: DX5/CD49b-Positive T Cells Are Not Synonymous with CD1d-Dependent NKT Cells.

Journal of immunology (Baltimore, Md. : 1950)·2024

Related Experiment Video

Updated: Mar 16, 2026

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

9.8K

Checkpoint Immunotherapy: Picking a Winner.

Michele W L Teng1, Rajiv Khanna1, Mark J Smyth2

  • 1QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.

Cancer Discovery
|August 4, 2016
PubMed
Summary

Identifying robust biomarkers for immune checkpoint blockade response is crucial. An adaptive immune signature in tumor biopsies during early therapy can distinguish melanoma patients who will respond from those who will not.

More Related Videos

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

2.0K
Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment
11:11

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

Published on: January 24, 2020

11.5K

Related Experiment Videos

Last Updated: Mar 16, 2026

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

9.8K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

2.0K
Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment
11:11

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

Published on: January 24, 2020

11.5K

Area of Science:

  • Oncology
  • Immunology
  • Biomarker Discovery

Background:

  • Immune checkpoint blockade (ICB) therapy has revolutionized cancer treatment.
  • Predictive biomarkers are essential to identify patients likely to benefit from ICB.
  • Current biomarkers for ICB response in melanoma are limited.

Discussion:

  • This study investigated changes in the tumor immune microenvironment during ICB therapy.
  • Researchers analyzed tumor biopsies from melanoma patients before and during early treatment.
  • The presence of an adaptive immune signature emerged as a key indicator.

Key Insights:

  • An adaptive immune signature in tumor biopsies, assessed early in therapy, can differentiate responders from non-responders to ICB.
  • This signature reflects the patient's immune system actively engaging with the tumor under treatment.
  • This finding offers a potential method for early prediction of treatment outcomes.

Outlook:

  • Further validation of this adaptive immune signature as a predictive biomarker is warranted.
  • This biomarker could guide treatment decisions and personalize melanoma therapy.
  • Future research may explore similar signatures in other cancer types treated with ICB.